Lurker Says pSivida Has “Tremendous Opportunity”
Nancy Lurker explains why she took over as CEO and president at pSivida and gives details on the company’s “outstanding” results of early clinical testing in the recurrence of uveitis. Lurker reveals the company’s plans for filing for regulatory approval in the EU and US and shares when the firm may be looking at a commercial release.
Nancy brings deep industry knowledge and is passionate about bridging the rapids from clinical R&D to life saving, and enhancing treatments for patients. She joined pSivida in September 2016 as President and CEO.